Ichthyosis: Clinical Trials

8 trials for Ichthyosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed. 8 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 18Completed 8
Phase 24Completed 4

Follow Ichthyosis: new trials by email Literature Review of Ichthyosis trials Research Report on Ichthyosis

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
ATR12-351 - Netherton Syndrome
Phase 1CompletedAzitra Inc.62024-06-162026-07-29
ADX-629 Therapy for Sjogren-Larsson Syndrome
ADX-629 - Sjogren-Larsson Syndrome
Phase 1 / Phase 2CompletedUniversity of Nebraska82023-01-022026-05-05
A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
DS-2325a, Placebo - Netherton Syndrome
Phase 1CompletedDaiichi Sankyo242022-11-082023-05-18
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
DS-2325a, Placebo - Netherton Syndrome
Phase 1CompletedDaiichi Sankyo642022-06-202023-03-06
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
SXR1096 cream, Placebo cream - Netherton Syndrome
Phase 1 / Phase 2CompletedSixera Pharma92021-12-072025-12-16
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment - Healthy Volunteers, Atopic Dermatitis
Phase 1CompletedNovartis Pharmaceuticals122011-05-012020-12-08
Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients
ROSE-010, Placebo - Irritable Bowel Syndrome Constipation Predominant
Phase 1 / Phase 2CompletedMayo Clinic522010-01-012013-05-31
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
Pimecrolimus 1% Cream - Netherton Syndrome
Phase 1 / Phase 2CompletedChildren's Hospital of Philadelphia32005-09-012019-08-14

Narrower conditions

Netherton Syndrome (6)  ·  Cerebral Palsy (1)  ·  Constipation (1)  ·  Dermatitis, Atopic (1)  ·  Eczema (1)  ·  Ichthyosis Bullosa of Siemens (1)  ·  Intellectual Disability (1)  ·  Irritable Bowel Syndrome (1)  ·  Muscle Spasticity (1)  ·  Retinal Diseases (1)  ·  Sjogren-Larsson Syndrome (1)  ·  Skin Diseases (1)  ·  Skin Diseases, Eczematous (1)  ·  Skin Diseases, Genetic (1)

Broader conditions

Congenital Abnormalities (8)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8)  ·  Genetic Diseases, Inborn (8)  ·  Infant, Newborn, Diseases (8)  ·  Keratosis (8)  ·  Skin Abnormalities (8)  ·  Skin and Connective Tissue Diseases (8)  ·  Skin Diseases (7)  ·  Skin Diseases, Genetic (7)  ·  Abnormalities, Multiple (6)  ·  Ichthyosiform Erythroderma, Congenital (6)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Signs and Symptoms (2)  ·  Brain Damage, Chronic (1)

Interventions

ADX-629 (1)  ·  Glucagon-Like Peptide 1 (1)  ·  WAS protein, human (1)  ·  glucagon-like peptide (7-37), valyl(10)- (1)  ·  pimecrolimus (1)

Sponsors

Daiichi Sankyo (2)  ·  Azitra Inc. (1)  ·  Children's Hospital of Philadelphia (1)  ·  Mayo Clinic (1)  ·  Novartis Pharmaceuticals (1)  ·  Sixera Pharma (1)  ·  University of Nebraska (1)

Countries

United States (7)  ·  Austria (1)  ·  France (1)  ·  Germany (1)  ·  Netherlands (1)  ·  Sweden (1)

Top investigators

Albert C Yan, MD (1)  ·  Maarten de Chateau, MD PhD (1)  ·  Mary Spellman, MD (1)  ·  Michael Camilleri, MD (1)  ·  William B Rizzo, MD (1)

Results publications

PMID 20083693, PMID 22517769

NIH funding

UL1RR024150 (1)